



SPECIAL ARTICLE

Time to diagnosis in paediatric inflammatory bowel disease: Key points for an early diagnosis[☆]



Javier Martín-de-Carpi^a, Santiago Jiménez Treviño^b, Gemma Pujol Muncunill^a,
Rafael Martín-Masot^c, Víctor Manuel Navas-López^{c,d,*}

^a Unidad para el Cuidado Integral de la Enfermedad Inflamatoria Intestinal Pediátrica (UCIEII-P), Servicio de Gastroenterología, Hepatología y Nutrición Pediátrica, Hospital Sant Joan de Déu, Barcelona, Spain

^b Sección de Gastroenterología, Hepatología y Nutrición Pediátrica, Área de Gestión Clínica de Pediatría, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

^c Sección de Gastroenterología y Nutrición Infantil, Hospital Materno Infantil, Hospital Regional Universitario de Málaga, Málaga, Spain

^d Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain

Received 5 August 2019; accepted 18 November 2019

Available online 11 April 2020

KEYWORDS

Inflammatory bowel disease;
Crohn's disease;
Ulcerative colitis;
Diagnostic delay

PALABRAS CLAVE

Enfermedad inflamatoria intestinal;
Enfermedad de Crohn;

Abstract Paediatric inflammatory bowel disease is not very common in Spain. Its onset can be silent and an early diagnosis reduces complications and sequelae related to the disease, and can improve the prognosis. It is advisable to define the different intervals into which the time until the diagnosis is divided, as well as the peculiarities and conditions in order to be able to act on them and, to avoid, as far as possible, the diagnostic delay. The aim of this review is to provide tools to reduce the time to diagnosis.

© 2019 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Tiempo hasta el diagnóstico en la enfermedad inflamatoria intestinal pediátrica: claves para un diagnóstico precoz

Resumen La enfermedad inflamatoria intestinal pediátrica continúa siendo poco prevalente en nuestro medio. El comienzo de los síntomas puede ser insidioso y el diagnóstico precoz permite disminuir las complicaciones y las secuelas de la enfermedad, así como mejorar el

[☆] Please cite this article as: Martín-de-Carpi J, Jiménez-Treviño S, Pujol-Muncunill G, Martín-Masot R, Navas-López VM. Tiempo hasta el diagnóstico en la enfermedad inflamatoria intestinal pediátrica: claves para un diagnóstico precoz. An Pediatr (Barc). 2020;92:242.

* Corresponding author.

E-mail address: victorm.navas.sspa@juntadeandalucia.es (V.M. Navas-López).

Colitis ulcerosa;
Retraso diagnóstico

pronóstico. Conviene definir los diferentes intervalos que componen el tiempo hasta el diagnóstico, así como sus peculiaridades y condicionantes para poder actuar sobre ellos y evitar, en la medida de lo posible, que se demore el diagnóstico, lo que repercutirá directamente sobre la salud de nuestros pacientes. Esta revisión pretende proporcionar herramientas para que cada vez sea más precoz el diagnóstico de la enfermedad.

© 2019 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Although the incidence and prevalence of inflammatory bowel disease (IBD) have increased in recent years,¹⁻³ it continues to be an infrequent disease at the primary care (PC) level. In addition, primary care paediatricians (PCPs) encounter and manage diseases that are much more prevalent and with features similar to those of IBD on a daily basis, such as functional abdominal pain disorders, which include functional dyspepsia, irritable bowel syndrome, abdominal migraine and functional abdominal pain not otherwise specified, with a prevalence of 10%–20% in the paediatric population.⁴ Another critical aspect is the heavy caseloads that PCPs are forced to manage, of about 1002 individuals with an official public health card (PHC) per PCP (source: Statistics Webpage of the Ministry of Health, Social Services and Equality of Spain). These 3 factors are among the most important reasons for the low level of suspicion and therefore the delayed diagnosis of these diseases. We ought to mention that efforts must also be made at the hospital level, including emergency care departments, inpatient services and outpatient clinics, to reduce the time to diagnosis (TD) of IBD. Since delays in diagnosis have deleterious consequences in the short, medium and long term, it is important that we identify and understand the causes of delays in order to establish adequate strategies to reduce the time elapsed between the onset of symptoms and the confirmation of diagnosis by a paediatric gastroenterologist.

Consequences of delayed diagnosis of paediatric inflammatory bowel disease

The TD of IBD is particularly relevant in children. Days of missed school due to disease, the undue prolongation of the diagnostic process and social isolation are some of the potential consequences of delayed diagnosis. Untreated symptoms, such as pain or diarrhoea, can have a direct impact on the physical and psychosocial development of children and adolescents with IBD. Delayed diagnosis is associated with an increased risk of complications,^{5,6} growth failure and delayed puberty,⁷ more extensive disease,⁸⁻¹⁰ a poorer response to medical treatment,⁸ an increased need of surgery⁵ and decreased health-related quality of life.¹¹ However, it does not seem to increase the risk of colectomy in patients with ulcerative colitis (UC).¹² The onset of paediatric IBD (PIBD) usually takes place in critical peri-

ods of life, characterised by physical changes (such as a high growth velocity), and psychosocial development, when the patient is developing a sense of self, potentially leading to role confusion. Growth failure, disorders of bone metabolism, delayed puberty, malnutrition and micronutrient or vitamin deficiencies are frequently associated with PIBD. Growth failure, which is less common in UC compared to Crohn's disease (CD), may be present at the time of diagnosis or occur during the follow-up. It is identified in 40%–50% of children with CD, persists in adulthood in 15%–20% of patients, and results in a final height below the target height in 20%. The TD of CD is one of the determinants of such growth failure.^{13,14} Thus, a large case series revealed a prevalence of growth failure of 9.4% in patients diagnosed within 3 months of onset, 15.7% in those diagnosed 3–6 months after onset and 22.3% in those diagnosed more than 6 months from onset.¹⁵ Delayed puberty generates feelings of isolation or rejection, more frequent than bullying, with a negative impact on relationships with peers. These patients have poor body image, decreased self-esteem, a higher risk of depression and anxiety about the future and, in the long term, missed opportunities in social and personal development.

Time to diagnosis, delay in diagnosis and missed opportunities for diagnosis: concepts and intervals

Delay in diagnosis (DD) has been defined as the time elapsed from the onset of symptoms to diagnosis. In our opinion, this is an unclear term, since for instance, in the hypothetical case that a patient with UC were diagnosed in 2 weeks, this time would be referred to as a 'delay', incorrectly in our opinion. To avoid confusion, it may be better to use the term TD to refer to the time elapsed between onset of symptoms and diagnosis (Fig. 1) and DD as wasted time in diagnosis that is not justifiable including missed opportunities for diagnosis during medical care episodes. The latter includes patient-related delays and health care system-related delays. We defined missed opportunities for diagnosis as any contacts with the health care system in which the diagnostic evaluation was not initiated despite the presence of one or more signs or symptoms suggestive of IBD being reported during the history taking. We defined medical care episodes as any physician-patient interaction in primary care, emergency care or hospital care settings. Determining what constitutes




Figure 1 Timeline to diagnosis. MOD, missed opportunities for diagnosis.

a reasonable TD is challenging, as this time will depend on each patient and clinical condition. The TD includes the care system response time, defined as those periods in which the patient is waiting to undergo diagnostic tests or to be seen by a specialist.

The TD comprises different intervals that deserve individual attention (Table 1).

Interval 1: from onset of symptoms to initial visit to a doctor

This interval depends on the patient and comprehends the time elapsed (usually unknown) between the onset of disease and the patient becoming aware of the symptoms and letting his or her parents know, or the parents becoming aware of there being a problem, plus the additional time that elapses before medical care is sought. The patient-related interval usually last days to weeks, and delays are usually due parents/patients lacking knowledge about relevant signs and symptoms (such as growth failure, asthenia, mild abdominal pain, etc.); the embarrassment elicited by gastrointestinal symptoms (diarrhoea, perianal complaints etc.) or anxiety regarding the possibility of receiving bad news (Table 2). Other factors that may be at play in this interval are the social environment of the patient, the geographical distance and accessibility of health care facilities, self-medication, believing that the symptoms are temporary, spiritual or religious beliefs and the use of alternative therapies to manage/alleviate symptoms. One aspect worth noting is that there are no differences in the duration of this interval between patients with relatives with IBD and patients with no family history of IBD.^{9,18}

Interval 2: from initial visit to a doctor to referral to paediatric gastroenterology

This interval usually lasts months and is particularly relevant, as there is previous evidence^{9,10,18} that it is the main

contributor to the TD. It depends strongly on the age of the patient, the type of IBD, the extension of disease, the disease activity and the presenting symptoms. This interval is mainly due to the physician not recognising the symptoms and attributing them to more frequent diseases, such as infections.

A nationwide register, SPIDER, that included 149 patients with a recent diagnosis of PIBD in Spain revealed that 73.5% visited more than 1 physician, 29.5% 3 or more physicians and up to 32.7% were evaluated more than 4 times by the same physician before being referred to a paediatrician specialised in paediatric gastroenterology. Of all patients, 52% had received a diagnosis of acute gastroenteritis; other initial diagnoses included lactose intolerance, irritable bowel syndrome, gluten intolerance, haemorrhoids, anal fissure, perianal abscess, recurrent abdominal pain, food allergy, short stature and gastritis.¹⁸

The 3 factors at play in this interval are the level of suspicion of IBD, the lines of communication with the reference unit that the patient needs to be referred to and previous experience with the disease. It is important that PCPs be aware of the possibility of IBD, as the prevalence and incidence of this disease are low. According to the Instituto Nacional de Estadística (National Institute of Statistics), the population aged less than 14 years in Spain as of December 31, 2018 was of 6 438 614 inhabitants, and the PHC/PCP ratio in 2018 was of 1002 children (source: Statistics Webpage of the Ministry of Health, Social Services and Equality of Spain), so given that the incidence of PIBD in Spain is of 2.8 cases per 10^5 inhabitants,¹ each paediatrician would encounter 0.18 cases of PIBD per year. A PCP working for 35 years is likely to manage a total of 6.3 patients with IBD over the course of his or her professional career. These data evince the need for PCPs to maintain a high level of suspicion, since compared with abdominal pain, which accounts for 8%–18% of all paediatric PC visits, very few patients in this setting will have IBD.

On the other hand, we need to take into account the waiting times and the pathways connecting PC settings to

Table 1 Time to diagnosis and intervals of diagnostic delay in PIBD.

Author	Patient-related delay	Health care system-related delay		Time to diagnosis
	Interval 1	Interval 2	Interval 3	
Schoepfer et al. (2019) ¹⁶	1 m (IQR, 1–4)	1 m (IQR, 1–7)		3 m (IQR, 1–9)
El Mouzan et al. (2019) ¹⁷	6 m (range, 1–24) ^a 2.4 m (range, 0.3–7) ^b	0.6 m (IQR, 0.4–3.4) ^{a,c} 0.8 m (0.5–3.9) ^{b,c}		8 m (range, 4–24) ^a 5 m (range, 2.1–8.8) ^b
Ricciuto et al. (2018) ¹⁰		2.96 m (IQR, 1.6–8.3) ^d	15 d (IQR, 7–45)	4.5 m (IQR, 2.1–8.8) 6.9 m (IQR, 2.9–12.6) ^a 2.4 m (IQR, 1.3–5.3) ^b
Jimenez et al. (2017) ¹⁸	15 d (IQR, 12–30) 21 d (IQR, 12–57) ^a 12 d (IQR, 12–27) ^b	2.5 m (IQR, 0.7–6.8) 4.2 m (IQR, 1.2–11) ^a 1.1 m (IQR, 0.5–2.6) ^b	12 d (IQR, 7.7–44) 14 d (IQR, 6.5–43.7) ^a 17 d (IQR, 12.5–36.9) ^b	4.2 m (IQR, 2.3–11.7) 9.4 m (IQR, 3–14) ^a 3.2 m (IQR, 1.4–5.0) ^b
Schoepfer et al. (2017) ⁹	1 m (IQR, 0–3) 0 m (IQR, 0–3) ^b	3 m (IQR, 1–9) ^c 2 m (IQR, 1–4) ^{b,c}		4 m (IQR, 2–8) ^a 2 m (IQR, 1–7) ^b
Arcos-Machancoses et al. (2014) ¹⁹	2 w (IQR, 1–3) ^a 1 w (IQR, 1–2.5) ^b	0.5 w (IQR, 0–1.25) ^a 2 w (IQR, 0–4) ^b	2 w (IQR, 1–4) ^a 5 w (IQR, 1.5–34) ^b	12 w (IQR, 3–51) ^a 12 w (IQR, 4–38) ^b
Timmer et al. (2011) ¹⁵				4 m (IQR, 2–8) 5 m (IQR, 2–10) ^a 3 m (IQR, 1–6) ^b
Sawczenko et al. (2003) ²⁰				5 m (IQR, 1–108) 6 m (IQR, 3.6–12) ^a 4.8 m (IQR, 2.4–8.4) ^b
Spray et al. (2001) ²¹				11.7 m (range, 1–84) ^a 5 m (range, 0.5–36) ^b
Heikenen et al. (1999) ²²				7.1 m (range, 0.25–36) ^a 6.7 m (range, 0.1–36) ^b

d, days; IQR, interquartile range; m, months; w, weeks.

^a Crohn's disease.

^b Ulcerative colitis.

^c Data correspond to intervals 2 and 3.

^d Data correspond to intervals 1 and 2.

Table 2 Factors that influence each interval.

	Factor
Interval 1	Lack of awareness of relevance of signs/symptoms of parents/patients Nonspecific symptoms: growth failure, asthenia, mild abdominal pain, etc. Embarrassment caused by gastrointestinal symptoms (diarrhoea, perianal complaints, etc) Anxiety at the possibility of receiving bad news Social environment of patient Geographical distance Accessibility of health care facilities Diagnostic error and self-medication Belief that the problem is temporary Spiritual or religious beliefs Use of alternative therapies to manage/alleviate symptoms
Interval 2	Age of patient Type of IBD Disease extension and location Severity of episode Presenting symptoms Lack of awareness regarding symptoms of the physician Believing the symptoms are caused by more frequent diseases
Interval 3	Organizational barriers Prioritization of more severe or complicated cases Performance of superfluous diagnostic tests that do not result in a conclusive diagnosis

the reference unit that these patients need to be referred to, factors that vary between autonomous communities. In some cases, and depending on the clinical condition of the patient, the waiting times may be excessive, so it is essential that alternative pathways for referral to paediatric gastroenterology services are established in order to shorten this interval.

This interval is significantly lower in patients with UC or IBD unclassified (IBDU), aged more than 11 years, with colonic (B2)²³ or ileocolonic (B3) forms of CD compared to CD with exclusive involvement of the distal 1/3 ileum (L1) and patients with any of the following signs or symptoms: diarrhoea, rectal bleeding, bloody diarrhoea, fever or weight loss.^{10,15} Abdominal pain was not a symptom that affected DD, but growth velocity was.¹⁰ This is particularly relevant, as growth failure in and of itself is not recognised as a sign of IBD and therefore the latter is not included in some of the algorithms for evaluation of short stature published in the literature,²⁴ even though the prevalence of growth failure is of 10%–56% in patients with CD and of 0%–10% in patients with UC, and that up to 46% will exhibit a decreased height velocity before the onset of any other symptom related to IBD. Furthermore, only 12% of children with IBD exhibit a normal growth velocity at the time of diagnosis.^{13–15}

Interval 3: from referral to paediatric gastroenterology to diagnosis

This interval usually lasts days, and delays are mainly due to organizational problems and the prioritization of more severe or complicated cases.^{10,18,19} In such cases, the presence of rectal bleeding contributes to a quicker diagnosis.¹⁰

One factor to take into account in this interval is that certain pathogens may produce mucosal lesions found that are similar to those associated with IBD on endoscopic examination (Table 3), which highlights the importance of a rigorous and standardised diagnosis in these patients. Thus, it is recommended that patients be evaluated in facilities with sufficient experience in the management of these cases,³¹ applying the Porto criteria³² and correctly identifying the IBD subtype, thus reducing the number of cases diagnosed as IBDU.³³

Generally, the main factors that play a role in DD are colonic involvement in CD, which acts as a protective factor leading to a quicker diagnosis, and diarrhoea or rectal bleeding, which also act as protectors. Risk factors associated with delayed diagnosis include onset before age 5 years and CD with isolated ileal involvement. Table 4 summarises the findings regarding the factors with an impact on the TD.

Alarm signs and symptoms

During interval 2, patients frequently receive one or several diagnoses as clinicians attempt to identify a plausible explanation for the clinical presentation out of a collection of diseases that are more prevalent than IBD. It is important that the duration of symptoms is established and that a diagnostic evaluation for IBD be initiated if they persist, that is, once they become an alarm sign/symptom. In other cases, the alarm signs are abnormal laboratory findings (Table 5).

Algorithms for referral to paediatric gastroenterology

None of the signs, symptoms or laboratory findings described above are pathognomonic for IBD, which is why efforts are

Table 3 Main infectious agents that cause lesions detected by endoscopy similar to those found in IBD.

Microorganism	Potential ileal involvement	Appearance similar to CD	Appearance similar to UC
<i>Plesiomonas shigelloides</i>	No	+	+++
<i>Entamoeba histolytica</i>	No	+	+++
<i>Aeromonas</i> spp.	No	+	++
<i>Clostridium difficile</i>	No	+	+
<i>Escherichia coli</i>	No	+	+
<i>Klebsiella oxytoca</i>	No	+	+
<i>Vibrio parahaemolyticus</i>	No	+	+
<i>Mycobacterium tuberculosis</i> ^b	Yes	+++	+
<i>Yersinia enterocolitica</i> ^a	Yes	+++	+
<i>Campylobacter</i> spp. ^a	Yes	++	+
<i>Salmonella enteritidis</i> ^a	Yes	+	++
<i>Shigella dysenteriae</i>	Yes	+	+++
Cytomegalovirus	Yes	+	+++

Adapted from Ye et al.,²⁵ Shivashankar et al.,²⁶ Gece et al.,²⁷ Bhaijee et al.,²⁸ Lamireau et al.²⁹ and Lamb et al.³⁰ *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, herpes simplex virus, cytomegalovirus, *Treponema pallidum*, *Giardia lamblia*, *Haemophilus ducreyi* and *Entamoeba histolytica* may cause proctitis in sexually active adolescents, consider possibility of sexually-transmitted disease.

^a Presence of microgranulomas on histological examination.

^b Presence of granulomas on histological examination.

Table 4 Factors involved in the diagnosis of IBD.

Factor	OR (95% CI)	Type of analysis	P	Ref.
Crohn's disease	0.62 (0.56–0.68) ^b	MV	NA	15
IBDU	0.80 (0.66–0.96) ^b	MV	NA	15
Family history	1.45 (1.07–1.96) ^b	UV	NA	15
	8.84 (0.98–76) ^{CD}	MV	.051	17
Age (year increase)	1.07 (1.06–1.08) ^{a,b}	MV	NA	15
Age <5 years	0.11 (0.018–0.66)	UV	.015	19
Age >10 years	15.625 (1.23–200) ^{UC}	MV	.034	17
L2 or L2 + L4	1.52 (1.25–1.85) ^b	MV	NA	15
L1	0.35 (0.13–0.95)	MV	.040	17
B3	0.83 (0.73–0.97) ^b	UV	NA	15
G1	0.66 (0.53–0.72) ^b	UV	NA	15
MEI	0.89 (0.77–1.01) ^b	UV	NA	15
Severity of episode	1.53 (1.00–2.38)	UV	.051	10
Diarrhoea	3.44 (1.35–9.0)	UV	.010	10
Rectal bleeding	3.03 (1.17–7.69)	UV	.021	10
Bloody diarrhoea	3.57 (1.19–10)	MV	.024	10
Fever	4.34 (0.93–20)	UV	.061	10
Weight loss	2.63 (1.01–6.6)	UV	.047	10
Delayed growth	0.48 (0.31–0.75)	MV	.001	10
Abdominal pain	2.94 (1.06–8.33)	UV	.037	10
Hypoalbuminaemia	1.26 (1.11–1.42)	MV	.001	10
Anaemia	1.05 (1.02–1.09)	UV	.001	10
Elevated CRP	1.02 (1.0–1.03)	UV	.065	10
Elevated ESR	1.03 (1.01–1.05)	UV	.015	10

Dependent variable: early diagnosis.

B3, Crohn's disease with stricturing behaviour; CD, Crohn's disease; CRP, C-reactive protein; EIM, extraintestinal manifestations; ESR, erythrocyte sedimentation rate; G1, growth failure; IBDU, inflammatory bowel disease unclassified; L, location of Crohn's disease (L1: distal 1/3 ileum; L2: colon; L3: ileocolon; L4: upper gastrointestinal); MV, multivariate; NA, not available; Ref, reference; UC, ulcerative colitis; UV, univariate.

^a Per year of age.

^b Hazard ratio.

Table 5 Signs, symptoms and laboratory findings suggestive of inflammatory bowel disease.

Symptoms	<p>Asthenia or anorexia</p> <p>Nocturnal bowel movements. Urgency.</p> <p>Diarrhoea lasting ≥ 2–4 weeks^a (Bristol stool chart type 5–7) or ≥ 2 episodes in the past 6 months with no other apparent cause</p> <p>Bloody diarrhoea lasting > 1 week^a</p> <p>Recurrent abdominal pain^b > 14 days or ≥ 2 episodes of abdominal pain in the past 5 months (not meeting ROMA IV criteria for a functional disorder)</p> <p>First-degree relative with IBD^{b,c}</p> <p>Unintended weight loss > 1 kg^{b,c}</p>
Signs	<p>Anal bleeding in absence of constipation (based on ROMA IV criteria)^c</p> <p>Recurrent mouth ulcers</p> <p>Recurrent perianal disease^c (abscesses,^a fistulae,^a fissures or skin tags)</p> <p>Prolonged fever^b</p> <p>Extraintestinal manifestations (episcleritis, scleritis, uveitis, erythema nodosum, gangrenous pyoderma, psoriasis, arthritis or digital clubbing)^c</p> <p>Delayed linear growth^{b,c} (at least 1 SD below the target height)</p> <p>Delayed puberty</p>
Laboratory findings	<p>Positive ASCA or ANCA antibodies^b</p> <p>Elevated faecal calprotectin^b</p> <p>Negative stool culture/parasites</p> <p>Haemoglobin concentration below the normal range for age and sex^c</p> <p>Hypertransaminasaemia</p> <p>Elevated CRP > 10 mg/L^{b,c}</p> <p>Platelet count $> 450 \times 10^9$/mm^{3c}</p> <p>Elevated ESR > 20 mm/h^{b,c}</p>

Adapted from Hyams et al.,³⁴ Holtman et al.,³⁵ Henderson et al.³⁶ and Atia et al.³⁷
 CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SD, standard deviation.

^a IBD-REFER major criterion.

^b IBD-REFER minor criterion.

^c Alarm signs and symptoms considered by Holtman et al.³⁵

being made to develop and validate algorithms that would increase the level of suspicion of physicians and PCPs and other specialists, facilitating the early referral of patients. Danese et al.³⁸ developed the Red Flag Index, consisting of 8 items rated on a scale from 2 to 5 points. A Red Flag Index greater than 8 points can discriminate adult patients with CD from those with suggestive symptoms with a sensitivity and a specificity of 94%, a positive likelihood ratio of 5.1 and a negative likelihood ratio of 0.066. Holtman et al.³⁵ conducted a prospective study that included 90 patients with gastrointestinal symptoms (prolonged diarrhoea or chronic/recurrent abdominal pain) referred from PC for assessment in a paediatric gastroenterology unit. The authors reported that adding faecal calprotectin results to the alarm symptoms (Table 4) significantly increased the area under the curve from 0.80 (0.67–0.92) to 0.97 (0.93–1.00), which did not occur with the inclusion of CRP. Decision curves confirmed that the combination of alarm symptoms with faecal calprotectin produced the diagnostic test strategy with the highest net benefit at reasonable threshold probabilities.

Recently, Turner et al. developed and validated the IBD-REFER criteria to guide the selection of patients requiring referral to paediatric and adult gastroenterology units due to suspected IBD. The IBD-REFER includes 3 major criteria

and 8 minor criteria, which we detail in Table 5 along with other criteria for referral published by other authors. The IBD-REFER criteria have exhibited a higher sensitivity and specificity when used both in children and adults compared to the Red Flags Index of the International Organization For the Study of Inflammatory Bowel Disease.³⁷

Proposed measures of improvement

In light of all of the above, we believe that collaboration in the framework of an interdisciplinary team is necessary to achieve the proposed objectives. The following are some of the strategies that we consider essential:

- Development and dissemination of guidelines and protocols in collaboration with PC to facilitate the early identification of these patients (Fig. 2).³⁹
- Establishment of quick and effective channels of communication between PC centres, hospitals and referral centres to allow early referral of these patients.⁴⁰
- Develop alternative referral routes to reduce the time to diagnosis (delivery of urgent or acute care by nursing staff, online visits, phone visits, etc.).






 When should I suspect an inflammatory bowel disease?	 What tests are required to be performed before referral to the hospital?	 Refer to Paediatric Gastroenterologist if ...
<p>A If your patient comes to your clinic with any of these symptoms or clinical history of:</p> <ul style="list-style-type: none"> • Diarrhoea (Bristol 5-7) lasting ≥ 14 days • Nocturnal bowel movements. Defecatory urgency • Bloody stools or active rectal bleeding • Unintentional weight loss of more than 1 kg • Abdominal pain lasting ≥ 14 days • Asthenia and/or anorexia • Family history of Inflammatory Bowel Disease <p>B Or if during physical examination for any of the A symptoms or for any other reason you find any of these findings or warning signs:</p> <ul style="list-style-type: none"> • Perianal disease: fistula, fissure, skin tags or perianal abscesses • Recurrent mouth sores • Extraintestinal manifestations such as: arthralgia, erythema nodosum, episcleritis, uveitis, psoriasis, gangrenous pyoderma, digital clubbing, etc. • Prolonged fever • Short stature /Growth failure /Delayed puberty 	<p>In case of strong suspicion, do not wait for any diagnostic test and contact with your Paediatric Gastroenterology Reference Unit to refer the patient.</p> <p>Otherwise the following tests are recommended: stool culture, ova and parasite exam, complete blood count, APR (CRP, ESR), albumin, AST/ALT and faecal calprotectin.</p> <p>C</p> <ul style="list-style-type: none"> • Stool culture, ova and parasite exam negative • High CRP >10 mg/L and/or ESR >20 mm/h • High faecal calprotectin >50 mg/g • Low albumin <3.5 g/L • High ALT and/or AST >2 ULN • Thrombocytosis $>450,000/mm^3$ or Anaemia¹ 	<p>[A and/or B] \pm C</p> <p>Contact information</p> <p> _____</p> <p> _____</p> <p><small>¹Rule out IBD, don't look for a plausible explanation for the symptoms. "What cannot be, cannot be and is also impossible".</small></p>

Figure 2 Leaflet summarising the alarm signs and symptoms, diagnostic tests to be performed and criteria for early referral.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

- Martín-de-Carpi J, Rodríguez A, Ramos E, Jiménez S, Martínez-Gómez MJ, Medina E, et al. Increasing incidence of pediatric inflammatory bowel disease in Spain (1996–2009). *Inflamm Bowel Dis.* 2013;19:73–80.
- Levine A, Turner D, Pfeffer Gik T, Amil Dias J, Veres G, Shaoul R, et al. Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: evaluation of the porto IBD group 'growth relapse and outcomes with therapy' (GROWTH CD) study. *Inflamm Bowel Dis.* 2014;20:278–85.
- Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet (London, England).* 2018;390(10114):2769–78.
- Blesa Baviera L. Trastornos digestivos funcionales pediátricos. In: *Crerios Roma IV AEPap*, editor. Curso de actualización Pediatría 2017. Madrid: Lúa Ediciones; 2017. p. 99–114.
- Zaharie R, Tantau A, Zaharie F, Tantau M, Gheorghe L, Gheorghe C, et al. Diagnostic delay in Romanian patients with inflammatory bowel disease: risk factors and impact on the disease course and need for surgery. *J Crohn's Colitis.* 2016;10:306–14.
- Schoepfer AM, Dehlavi MA, Fournier N, Sfroneeva E, Straumann A, Pittet V, et al. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. *Am J Gastroenterol.* 2013;108:1744–53.
- Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. *Pediatrics.* 2006;118:124–9.
- Moon CM, Jung SA, Kim SE, Song HJ, Jung Y, Ye BD, et al. Clinical factors and disease course related to diagnostic delay in Korean Crohn's disease patients: results from the CONNECT study. *PLoS One.* 2015;10:e0144390.
- Schoepfer AM, Vavricka S, Sfroneeva E, Fournier N, Manser C, Frei P, et al. Systematic evaluation of diagnostic delay in pediatric inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* 2017;64(2):245–7.
- Ricciuto A, Fish JR, Tomalty DE, Carman N, Crowley E, Popalis C, et al. Diagnostic delay in Canadian children with inflammatory bowel disease is more common in Crohn's disease and associated with decreased height. *Arch Dis Child.* 2018;103:319–26.
- Pellino G, Sciaudone G, Selvaggi F, Riegler G. Delayed diagnosis is influenced by the clinical pattern of Crohn's disease and affects treatment outcomes and quality of life in the long term: a cross-sectional study of 361 patients in Southern Italy. *Eur J Gastroenterol Hepatol.* 2015;27:175–81.
- Krishna M, Britto S, Qian J, Ihekweazu F, Rodriguez JR, Kellermayer R. Diagnostic delay and colectomy risk in pediatric ulcerative colitis. *J Pediatr Surg.* 2019. S0022-3468 (19) 30220-9.
- Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for the management of growth failure in childhood inflammatory bowel disease. *Inflamm Bowel Dis.* 2008;14:839–49.
- Gasparetto M, Guariso G. Crohn's disease and growth deficiency in children and adolescents. *World J Gastroenterol.* 2014;20:13219–33.
- Timmer A, Behrens R, Buderus S, Findeisen A, Hauer A, Keller K-M, et al. Childhood onset inflammatory bowel disease: predictors of delayed diagnosis from the CEDATA German-language pediatric inflammatory bowel disease registry. *J Pediatr.* 2011;158:467–73, e2.
- Schoepfer A, Santos J, Fournier N, Schibli S, Spalinger J, Vavricka S, et al. Systematic analysis of the impact of diagnostic delay on bowel damage in paediatric versus adult onset Crohn's disease. *J Crohn's Colitis.* 2019;13:1334–42.
- El Mouzan M, AlSaleem B, Hasosah M, Al-Hussaini A, Al Anazi A, Saadah O, et al. Diagnostic delay of pediatric inflammatory bowel disease in Saudi Arabia. *Saudi J Gastroenterol.* 2019;25:257–61.
- Jimenez S, Navas-López V, Martín-de-Carpi J, Rodríguez-Martínez A, Segarra O, Peña-Quintana L. Diagnostic delay in pediatric inflammatory bowel disease in Spain: the SPIDER registry. *J Pediatr Gastroenterol Nutr.* 2017;65:S28–9.
- Arcos-Machancoses JV, Donat-Aliaga E, Polo-Miquel B, Masip-Simo E, Ribes-Koninckx C, Pereda-Perez A. Retraso diagnóstico en la enfermedad inflamatoria intestinal pediátrica. Descripción y estudio de los factores de riesgo. *An Pediatr.* 2015;82:247–54.

20. Sawczenko A, Lynn R, Sandhu BK. Variations in initial assessment and management of inflammatory bowel disease across Great Britain and Ireland. *Arch Dis Child*. 2003;88:990–4.
21. Spray C, Debelle GD, Murphy MS. Current diagnosis, management and morbidity in paediatric inflammatory bowel disease. *Acta Paediatr*. 2001;90:400–5.
22. Heikenen JB, Werlin SL, Brown CW, Balint JP. Presenting symptoms and diagnostic lag in children with inflammatory bowel disease. *Inflamm Bowel Dis*. 1999;5:158–60.
23. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. *Inflamm Bowel Dis*. 2011;17:1314–21.
24. Cheetham T, Davies JH. Investigation and management of short stature. *Arch Dis Child*. 2014;99:767–71.
25. Ye Z, Lin Y, Cao Q, He Y, Xue L. Granulomas as the most useful histopathological feature in distinguishing between Crohn's disease and intestinal tuberculosis in endoscopic biopsy specimens. *Med (United States)*. 2015;94, e2157–e2157.
26. Shivashankar R, Lichtenstein GR. Mimics of inflammatory bowel disease. *Inflamm Bowel Dis*. 2018;24:2315–21.
27. Gecse KB, Vermeire S. Differential diagnosis of inflammatory bowel disease: imitations and complications. *Lancet Gastroenterol Hepatol*. 2018;3:644–53.
28. Bhaijee F, Arnold C, Lam-Himlin D, Montgomery EA, Voltaggio L. Infectious mimics of inflammatory bowel disease. *Diagnostic Histopathol*. 2015;21:267–75.
29. Lamireau T, Enaud R. Differential diagnosis of inflammatory bowel disease. In: Mamula P, Grossman AB, Baldassano RN, Kelsen JR, Markowitz JE, editors. *Pediatric inflammatory bowel disease: Third edition*. 3rd ed. Cham Switzerland: Springer International Publishing AG; 2017. p. 199–209.
30. Lamb CA, Lamb EIM, Mansfield JC, Sankar KN. Sexually transmitted infections manifesting as proctitis. *Frontline Gastroenterol*. 2013;4:32–40.
31. Turner D, Carle A, Steiner SJ, Margolis PA, Colletti RB, Russell RK, et al. Quality items required for running a paediatric inflammatory bowel disease centre: an ECCO paper. *J Crohns Colitis*. 2017;11:981–7.
32. Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. *J Pediatr Gastroenterol Nutr*. 2014;58:795–806.
33. Birimberg-Schwartz L, Zucker DM, Akriv A, Cucchiara S, Cameron FL, Wilson DC, et al. Development and validation of diagnostic criteria for IBD subtypes including IBD-unclassified in children: a multicentre study from the pediatric I.B.D. Porto Group of ESPGHAN. *J Crohns Colitis*. 2017;11:1078–84.
34. Hyams JS, di Lorenzo C, Saps M, Shulman RJ, Staiano A, Van Tilburg M. Childhood functional gastrointestinal disorders: child/adolescent. *Gastroenterology*. 2016;150:1456–68.e2.
35. Holtman GA, Lisman-van Leeuwen Y, Kollen BJ, Norbruis OF, Escher JC, Walhout LC, et al. Diagnostic test strategies in children at increased risk of inflammatory bowel disease in primary care. *PLoS One*. 2017;12:e0189111.
36. Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. *Am J Gastroenterol*. 2014;109:637–45.
37. Atia O, Focht G, Assa A, Yerushalmi B, Shaoul R, Shouval DS, et al. DOP31 development and validation of the IBD-REFER criteria: when should a general practitioner or paediatrician refer a patient for suspected IBD? *J Crohn's Colitis*. 2019;13 Suppl. 1. S043–S043.
38. Danese S, Fiorino G, Mary JY, Lakatos PL, D'Haens G, Moja L, et al. Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn's disease: an IOIBD initiative. *J Crohn's Colitis*. 2015;9:601–6.
39. López M, Ros I, García R, Cénarro T. Enfermedad inflamatoria intestinal pediátrica en atención primaria [Internet] [last access 18 jul 2018]. Available in: <https://www.aepap.org/sites/default/files/documento/archivos>.
40. Rufo PA, Denson LA, Sylvester FA, Szigethy E, Sathya P, Lu Y, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. *J Pediatr Gastroenterol Nutr*. 2012;55:93–108.